Statins in lymphangioleiomyomatosis: Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling

American Journal of Respiratory Cell and Molecular Biology

Volumn 49, Issue 5, 2013, Pages 704-709

  Atochina Vasserman, Elena N ^a   Goncharov, Dmitry A ^a   Volgina, Alla V ^a   Milavec, Megan ^a   James, Melane L ^a   Krymskaya, Vera P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Apoptosis; LAM; MTOR; TSC; TSC2

Indexed keywords

ATORVASTATIN; CASPASE 3; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RAPAMYCIN; SIMVASTATIN; TUBERIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL GROWTH; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; GROWTH INHIBITION; HUMAN; HUMAN CELL; LYMPHANGIOLEIOMYOMATOSIS; MOUSE; NONHUMAN; NULL CELL; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; CASPASE 3; CELL LINE; CELL PROLIFERATION; CELL SHAPE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEPTANOIC ACIDS; HUMANS; LYMPHANGIOLEIOMYOMATOSIS; MICE; MULTIPROTEIN COMPLEXES; PROTO-ONCOGENE PROTEINS C-AKT; PYRROLES; SIGNAL TRANSDUCTION; SIMVASTATIN; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84887052370     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2013-0203RC     Document Type: Article

References (48)

1. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006;355: 1345-1356.
2. Henske EP, McCormack FX. Lymphangioleiomyomatosis: a wolf in sheep's clothing. J Clin Invest 2012;122: 3807-3816.
3. McManus EJ, Alessi DR. TSC1-TSC2: a complex tale of PKB-mediated S6K regulation. Nat Cell Biol 2002;4:E214-E216.
4. Goncharova EA, Goncharov DA, Eszterhas A, Hunter DS, Glassberg MK, Yeung RS, Walker CL, Noonan D, Kwiatkowski DJ, Chou MM, et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation: a role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis. J Biol Chem 2002;277: 30958-30967.
5. Goncharova EA, Goncharov DA, Spaits M, Noonan D, Talovskaya E, Eszterhas A, Krymskaya VP. Abnormal smooth muscle cell growth in LAM: role for tumor suppressor TSC2. Am J Respir Cell Mol Biol 2006;34: 561-572.
6. Kwiatkowski DJ, Zhang H, Bandura JL, Heiberger KM, Glogauer M, el- Hashemite N, Onda H. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in tsc1 null cells. Hum Mol Genet 2002;11: 525-534.
7. Yuan H-X, Xiong Y, Guan K-L. Nutrient sensing, metabolism, and cell growth control. Mol Cell 2013;49: 379-387.
8. Kenerson HL, Aicher LD, True LD, Yeung RS. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 2002;62: 5645-5650.
9. Lee L, Sudentas P, Donohue B, Asrican K, Worku A, Walker V, Sun Y, Scgmidt K, Albert MS, El-Hashemite N, et al. Efficacy of a rapamycin analog (CCI-779) and IFN-g in tuberous sclerosis mouse models. Genes Chromosomes Cancer 2005;42: 213-227.
10. Krymskaya VP, Goncharova EA. PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects. Cell Cycle 2009;8: 403-413.
11. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011;364: 1595-1606.
12. Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2012;381: 125-132 .
13. Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006;59: 490-498.
14. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008;358: 140-151.
15. Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL, Watson PC, Howe CJ, Doyle T, Pointon K, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res 2011;17: 4071-4081.
16. Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013;381: 817-824.
17. Krymskaya VP. Treatment option(s) for pulmonary lymphangioleiomyomatosis: progress and current challenges. Am J Respir Cell Mol Biol 2012;46: 563-565.
18. Dabora SL, Franz DN, Ashwal S, Sagalowsky A, DiMario FJ Jr, Miles D, Cutler D, Krueger D, Uppot RN, Rabenou R, et al.Multicenter phase 2 trial of sirolimus for TS: kidney angiomyolipomas and other tumors regress and VEGF-D levels decrease. PLoS ONE 2011;6:e23379.
19. Goncharova E,Goncharov D, Noonan D, Krymskaya VP. TSC2modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the RAC1 GTPase. J Cell Biol 2004;167: 1171-1182.
20. Finlay GA, Malhowski AJ, Liu Y, Fanburg BL, Kwiatkowski DJ, Toksoz D. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho gtpase function and reduced mTOR/S6 kinase activity. Cancer Res 2007;67: 9878-9886.
21. Goncharova EA, Goncharov DA, Lim PN, Noonan D, Krymskaya VP. Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 2006; 34: 473-480.
22. Goncharova EA, Goncharov DA, Li H, Pimtong W, Lu S, Khavin I, Krymskaya VP. mTORC2 is required for proliferation and survival of TSC2-null cells. Mol Cell Biol 2011;31: 2484-2498.
23. Sahai E, Marshal CJ. Rho-GTPases and cancer. Nat Rev Cancer 2002;2: 133-142.
24. Demierre M-F, Higgins PDR, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005;5: 930-942.
25. El-Chemaly S, Taveira-DaSilva A, Stylianou MP, Moss J. Statins in lymphangioleiomyomatosis: a word of caution. Eur Respir J 2009; 34: 513-514.
26. Loboda A, Jazwa A, Jozkowicz A, Molema G, Dulak J. Angiogenic transcriptome of human microvascular endothelial cells: effect of hypoxia, modulation by atorvastatin. Vascul Pharmacol 2006;44: 206-214.
27. Young LR, VanDyke R, Gulleman PM, Inoue Y, Brown KK, Schmidt LS, Linehan WM, Hajjar F, Kinder BW, Trapnell BC, et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest 2010;138: 674-681.
28. Goncharova EA, Goncharov DA, FehrenbachM, Khavin I, Duka B, Hino O, Colby TV, Merrilees MJ, Haczku A, Albelda SM, Krymskaya VP. Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM). Sci Transl Med 2012;4: 154ra134.
29. Lee N,Woodrum C, Nobil A, Rauktys A,MessinaM, Dabora S. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. BMC Pharmacol 2009;9: 8.
30. Kobayashi T, Minowa O, Kuno J, Mitani H, Hino O, Noda T. Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line TSC2 mutation in mice. Cancer Res 1999;59: 1206-1211.
31. Qi XF, Zheng L, Lee KJ, Kim DH, Kim CS, Cai DQ, Wu Z, Qin JW, Yu YH, Kim SK. HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ros generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway. Cell Death Dis 2013;4:e518.
32. Amaravadi R, Thompson CB. The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 2005;115: 2618.
33. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006;6: 729-734.
34. Kyriakis JM, Avruch J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Phys Rev 2012;92: 689-737.
35. Andersen J, Kornbluth S. The tangled circuitry of metabolism and apoptosis. Mol Cell 2013;49: 399-410.
36. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, Hall MN. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004;6: 1122-1128.
37. Saci A, Cantley Lewis C, Carpenter Christopher L. Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size. Mol Cell 2011;42: 50-61.
38. Heart Protection Study Collaborative Group, Bulbulia R, Bowman L, Wallendszus K, Parish S, Armitage J, Peto R, Collins R. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet 2011;378: 2013-2020.
39. Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf 2010;9: 603-621.
40. Mihos CG, Artola RT, Santana O. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review. Rheumatol Int 2012;32: 287-294.
41. Bergdahl A, Persson E, Hellstrand P, Swärd K. Lovastatin induces relaxation and inhibits l-type Ca21 current in the rat basilar artery. Pharmacol Toxicol 2003;93: 128.
42. Tasat DR, Yakisich JS. Expanding the pleiotropic effects of statins: attenuation of air pollution-induced inflammatory response. Am J Physiol Lung Cell Mol Physiol 2012;303:L640-L641.
43. Zhou Z, Rahme E, Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J 2006;151: 273-281.
44. Neuvonen P, Backman J, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet 2008;47: 463-474.
45. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005;45: 89-118.
46. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012;367: 1792-1802.
47. Janda S, Park K, FitzGerald JM, Etminan M, Swiston J. Statins in COPD: a systematic review. Chest 2009;136: 734-743.
48. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipidlowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80: 565-581.